University of Bristol-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013185)
◆英語タイトル:University of Bristol - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013185
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:48
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
University of Bristol (UOB) is an educational service provider that offers undergraduate and postgraduate courses and research services. The university offers courses in arts, biomedical sciences, engineering, medical and veterinary sciences, dentistry, science, and social sciences and law. It operates schools of earth sciences, experimental psychology, and nanoscience and quantum information. UOB’s sport, exercise and health department offers a network of facilities for healthy student experience. The university collaborates with different organizations to enable them to develop innovative solutions. It also offers research study services. UOB is headquartered in Bristol, the UK.

University of Bristol – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
University of Bristol, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of Bristol, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of Bristol, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of Bristol, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
University of Bristol, Medical Devices Deals, 2011 to YTD 2017 10
University of Bristol, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
University of Bristol, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Azellon Raises USD2 Million in Venture Financing 12
Partnerships 14
Evotec Enters into Partnership with University of Bristol, University of Cambridge and Mario Negri Institute for Pharmacological Research 14
MRC Technology Enters Into Second Research Agreement With University of Bristol 16
MRC Technology Enters Into Agreement With University of Bristol To Develop TrkA Antagonists 17
Licensing Agreements 18
Achieve Life Science Enters into Licensing Agreement with University of Bristol 18
Topokine Therapeutics Enters into Licensing Agreement with University of Bristol 19
University of Bristol – Key Competitors 20
University of Bristol – Key Employees 21
University of Bristol – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Government and Public Interest 23
Nov 16, 2017: Bristol wins grant to tackle antibacterial drug resistance in Thailand 23
Oct 31, 2017: Revolutionary Stem Cell Therapy for Knees, Also Known as Living ‘bandage’ 24
Aug 21, 2017: Bristol scientists to study oral bacteria that cause heart infection 25
Aug 07, 2017: Study of protein cages strengthens Bristol’s position at forefront of synthetic biology 26
May 18, 2017: Cystic fibrosis study offers new understanding of silent changes in genes 27
Sep 15, 2016: Monitoring prostate cancer offers the same survival chance as surgery or radiotherapy over 10 years, but treatment reduces risk of cancer progression 28
Sep 01, 2016: New algorithm could help GPs reduce antibiotic use in children with coughs and RTIs 30
May 19, 2016: MRC announces cross-council awards worth nearly £10m to tackle antibiotic resistance 31
Mar 21, 2016: Autism genes are in all of us, new research reveals 33
Mar 16, 2016: Antibiotic resistance ‘high among children with urinary tract infections’ 34
Mar 15, 2016: Pregnant mother’s weight, glucose and blood pressure affect baby’s size 35
Mar 15, 2016: High antibiotic resistance levels in children could leave some treatments ineffective 36
Mar 08, 2016: More than two million people are co-infected with HIV and hepatitis C 37
Feb 29, 2016: Bristol scientists to study potential new way of treating diabetes 38
Feb 23, 2016: University wins strategic awards to support translational research 39
Feb 12, 2016: Genome studies can help identify lifestyle risks for diseases 40
Feb 10, 2016: Stronger evidence found for link between prenatal exposure to paracetamol and the risk of developing asthma 41
Jan 18, 2016: New Alzheimer’s disease drug trial opens more sites across the South West 42
Jan 14, 2016: Study by Bristol researchers to examine obesity treatment 43
Jan 13, 2016: Common dementia drug found to improve Parkinson’s symptoms 44
Product News 45
Jul 28, 2017: Ground-Breaking Alzheimer’s Trial Available To Patients Across Northern Ireland 45
Mar 24, 2017: Major breakthrough in the manufacture of red blood cells 46
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
University of Bristol, Pharmaceuticals & Healthcare, Key Facts 2
University of Bristol, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of Bristol, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of Bristol, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of Bristol, Deals By Therapy Area, 2011 to YTD 2017 9
University of Bristol, Medical Devices Deals, 2011 to YTD 2017 10
University of Bristol, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Azellon Raises USD2 Million in Venture Financing 12
Evotec Enters into Partnership with University of Bristol, University of Cambridge and Mario Negri Institute for Pharmacological Research 14
MRC Technology Enters Into Second Research Agreement With University of Bristol 16
MRC Technology Enters Into Agreement With University of Bristol To Develop TrkA Antagonists 17
Achieve Life Science Enters into Licensing Agreement with University of Bristol 18
Topokine Therapeutics Enters into Licensing Agreement with University of Bristol 19
University of Bristol, Key Competitors 20
University of Bristol, Key Employees 21
University of Bristol, Subsidiaries 22

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ University of Bristol-製薬・医療分野:企業M&A・提携分析(University of Bristol - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆